Home / Market News / $ETON
benzinga Corporate Catalyst Impact 65/100 ● positive

Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027

Oct 14, 2026, 10:58 AM UTC · Primary ticker $ETON

Eton Pharmaceuticals and Aquestive Therapeutics have entered an exclusive U.S. license and supply agreement for LIBERVANT buccal film, a potential new treatment for seizure clusters. This partnership aims to tap into a significant market opportunity exceeding $450 million annually, offering a differentiated product with strong patient preference.

Eton Pharmaceuticals and Aquestive Therapeutics have announced an exclusive U.S. license and supply agreement for LIBERVANT, a buccal film for seizure clusters. This is a significant development as it positions both companies to enter a substantial market, estimated at over $450 million annually, with a product that has shown strong patient preference over existing treatments. The long-term implication is a potential new revenue stream and market share gain for both companies, particularly Eton as the commercialization partner, starting in April 2027, subject to FDA approval. For traders, the key opportunity lies in the potential for future growth driven by this new product, though the 2027 launch date means short-term impact will be limited to sentiment and initial valuation adjustments.

$ETON positive New product license, market expansion
$AQST positive Licensing agreement, supply revenue
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.